irbesartan/hydroklortiazid actavis 150 mg / 12.5 mg
actavis group ptc ehf - irbesartan / hydroklortiazid - tablett, filmdrasjert - 150 mg / 12.5 mg
irbesartan/hydroklortiazid actavis 300 mg / 25 mg
actavis group ptc ehf - irbesartan / hydroklortiazid - tablett, filmdrasjert - 300 mg / 25 mg
losartan/hydrochlorothiazide bluefish 100 mg / 25 mg
bluefish pharmaceuticals ab - losartankalium / hydroklortiazid - tablett, filmdrasjert - 100 mg / 25 mg
losartan/hydrochlorothiazide bluefish 50 mg / 12.5 mg
bluefish pharmaceuticals ab - losartankalium / hydroklortiazid - tablett, filmdrasjert - 50 mg / 12.5 mg
pravachol 40 mg
bristol-myers squibb ab - pravastatin - tablett - 40 mg
pravachol 20 mg
bristol-myers squibb ab - pravastatin - tablett - 20 mg
pravastatin sandoz 40 mg
sandoz - københavn - pravastatinnatrium - tablett - 40 mg
pravastatin sandoz 20 mg
sandoz - københavn - pravastatinnatrium - tablett - 20 mg
zofenil comp 30 mg / 12.5 mg
menarini international o.l. s.a. - zofenoprilkalsium / hydroklortiazid - tablett, filmdrasjert - 30 mg / 12.5 mg
cancidas (previously caspofungin msd)
merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimykotika for systemisk bruk - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.